Nagata, Yutaka
Esaki, Motohiro http://orcid.org/0000-0001-8421-509X
Moriyama, Tomohiko
Hirano, Atsushi
Umeno, Junji
Maehata, Yuji
Torisu, Takehiro
Matsumoto, Takayuki
Kitazono, Takanari
Article History
Received: 10 April 2018
Accepted: 16 September 2018
First Online: 22 September 2018
Compliance with ethical standards
:
: Motohiro Esaki received research grants from, Mitsubishi Tanabe Pharma (MTP), EA Pharma (EAP), AbbVie GK (AGK), ZERIA Pharma (ZP), and Asahi Kasei Medical (AKM), and lecture fee from MTP and AGK. Takayuki Matsumoto received research grants from MTP, EAP, and Nippon Kayaku, and lecture fee from MTP, EAP, KYORIN Pharma, AGK, Janssen Pharma, Mochida Pharma, Pfizer, ZP, and AstraZeneca, and advisory fee from JIMRO, Kissei Pharma, and Takeda Pharma (TP). Takanari Kitazono received research grants from Daiichi Sankyo (DS), TP, MTP, Astellas Pharma, Chugai Pharma, MSD, Boehringer Ingelheim, Bristol-Myers, Kyowa Hakko Kirin, AKM, Otsuka Pharma, and Torii Pharma, and lecture fee from DS. The remaining authors disclose no conflicts of interest. This study did not receive any financial support.